TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Acetabular Component Inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVC isolation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial Colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: decrement of infiltration size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Seroprotected Against Diphtheria and Tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Titers of Anti-pertussis Toxoid (Anti-PT), Anti-pertactin Toxoid (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Seroprotected Against Poliovirus Type 1, Polio 2 and Polio 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intima Media Thickness (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid wall thickness on MRI (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of brain infarctions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reductions in smoking initiation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Time to Beginning of Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Health Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pupillometry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CYP2D6 phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Paraprotein Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Free Light Chain (FLC) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tolerability Survey Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of the severity of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of the severity of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants That Experienced Serious Adverse Events (SAEs), Death or an Adverse Event (AE) Leading to Study Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Potentially Clinically Significant Changes in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of study subjects having coronary Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of study subjects having Major Adverse Cardiac Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of study subjects with endpoint of death
Endpoint domain: Mortality/survival
Primary endpoint: days on ventilator support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Length of stay ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence infections
Endpoint domain: Adverse events/effects
Primary endpoint: Whole body Insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulinaemic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Range of Motion of the Shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Morning and Evening Subject-Reported Reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression survival
Endpoint domain: Mortality/survival
Primary endpoint: Total Consumption of Fentanyl
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from Baseline in Sociocultural Attitudes towards Appearance Questionnaire-4
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in Eating Attitudes Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ELR+CXCL cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change score in Behavioral Inattention Test (BIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of symptoms related to morning activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline of Growth Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Curve of Growth Hormone Over Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Hemoglobin A1C values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: COVID-19 disease diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Neurological Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hair removal efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal endothelial cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation of endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of hexagonal cells of the cells marked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission by Disease Activity Score - 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of (near) incidents
Endpoint domain: Adverse events/effects
Primary endpoint: total amount of sedatives administered
Endpoint domain: Physiological/clinical
Primary endpoint: time to wake up (after sedation is stopped), comfort scale
Endpoint domain: Physiological/clinical
Primary endpoint: Standard deviation value of blood pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EFL at PEP 5 cmH2O
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MRI tumour regression grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline in Ryegrass specific-IgG4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Achieved FeNO < 25 Ppb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Change in Untrimmed Distal Specific Airway Volumes at TLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early response to radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in oxygen saturation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IFN-beta gene and/or protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Window Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of clinical remission (CDAI score < 150 at Week 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort assessment using the dry eye questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comfort assessment using the ocular surface disease index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of indication signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose metabolic rates in striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in four-metre gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of zinc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: long-term outcomes in hospitalized COVID-19 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Disease Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Recurrent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Postoperative pulmonary complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evidence of biological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Levels of Calgranulin C (S100A12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Driving Simulator Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Microscopic Signs of Parietal Cell Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients With First Recurrent Cerebral Infarction
Endpoint domain: Mortality/survival
Primary endpoint: intraoperative massive hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Subjective rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to discontinuation of initial antipsychotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline-corrected Cmax of HGP0918
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline-corrected AUCt of HGP0918
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of HGP0816
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of HGP0816
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Developing Cytomegalovirus (CMV) Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Total Morphine Equivalents Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Bodyweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Kidney Disease Quality of Life Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of transient elastography for diagnosing liver fibrosis ≥F2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients with High Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose of ENMD-2076
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Allograft Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Neuralgia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levobupivacaine free plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% fall in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients hospitalized for acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: composite of infarct-related artery on angiogram, death or recurrent MI
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients achieving urine osmolality < 270 mOsm/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in systolic BP (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stability of changes in food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response Rates of Radiographically Measurable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological Improvement - minor (HI-minor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Advanced colorectal adenoma detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Extent of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFF in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: re-bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: re-hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Decline in ALSFRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in absolute total hemoglobin concentration ([THb])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in tissue oxygen saturation (StO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative inner retinal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Global safety
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titres (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Received Treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Number of Tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Vasoactive role of Soluble epoxide hydrolase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Headache Intensity Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first episode of culture-confirmed influenza-illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: concentration of pro- and anti-inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Objective sleep parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid Symptom Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable Symptom Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Possibly and Probably Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Histologic evaluation of the endometrium at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical evaluation (hormone measurements) of uterine tissue at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Biochemical evaluation of sera, obtained just prior to treatment and at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular assessment of gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to weekly walking sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: type and prevalence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: change in cardiorespiratory fitness (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative occurrence of VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in 24-Hour Mean Weighted Glucose (MWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sympathetic nerve reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of nosocomial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrence rate of vaginal prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected logMAR visual acuity score of the amblyopic eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of glycocalyx thickness regarding clinical course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of glycocalyx thickness regarding mortality
Endpoint domain: Mortality/survival
Primary endpoint: Hospital Anxiety and Depression Scale (HADS-Total)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative desflurane consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedation scores for OASS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reflux symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of dyspeptic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of rhMBL
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Pericardial Access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Trust at M3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trust at M10
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness at M3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness at M10
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Potential at M3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Potential at M10
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Costs at M3
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Content validity of the IDSIQ™
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: treatment response based on [F-18] FLT results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total activity and moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in oncotic pressure in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28 (CRP))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standardized uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GFR measured by inulin Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Coronary flow velocity/coronary flow reserve (CFV/CFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HsCRP release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentration of Wnt5a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of sFRP1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of sFRP5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of WIF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working Memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibodies Before and After Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With a ≥ 4-Fold Rise in Serum Hemagglutination Inhibition Antibody Titers Post-Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes